Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19

doi:10.13523/j.cb.2106014

China Biotechnology

2021, Vol. 41

Issue (7): 110-121 DOI: 10.13523/j.cb.2106014

Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19

YUN Tao¹,GONG Yue^2,^*(

),GU Peng¹,XU Bing-bing³,LI Jin⁴,ZHAO Xi-chen⁴

1 China Science and Technology Exchange Center, Beijing 100045, China
2 National Science Library, Chinese Academy of Sciences, Beijing 100190, China
3 National Library of China, Beijing 100081, China
4 Macau University of Science and Technology, Macau　999078, China

Download:

HTML

PDF(3175KB) HTML
Export: BibTeX | EndNote (RIS)

Abstract

COVID-19 that broke out at the end of 2019 swept the world. It has become a major global health and security challenge that requires the joint efforts over the world. Through hard work, China has basically controlled the domestic epidemic, and has made significant progress in related research and public health products. At the same time, China has strengthened international scientific and technological cooperation with participating countries in the “Belt and Road” Initiative.The progress of international S&T cooperation between China and related countries to combat COVID-19 in terms of basic research, research projects, etc. were summarized, and it can be seen that: China has formed a complex network of intersected and diversified nodes with the countries participating in the “Belt and Road” Initiative, and mainly with countries in Southeast Asia, Central and Eastern Europe and Western Asia; The institutes in China and countries participating in the “Belt and Road” Initiative has launched a lot of substantive research in the areas of prevention, control, epidemiology and treatment, and aid cooperation accounted for a large proportion. In the future, China should strengthen the biotechnology industry cooperation and technology transfer, give full play to the demonstration effect of the regional fulcrum countries, and build a richer, closer and more pragmatic scientific and technological cooperation relationship under the “Belt and Road” Initiative.

Key words： SARS-CoV-2 2019-nCoV COVID-19 “Belt and Road” initiative S&T cooperation

Received: 08 June 2021 Published: 03 August 2021

ZTFLH:

Q819

Corresponding Authors: Yue GONG E-mail: gongy@mail.las.ac.cn

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Tao YUN
	Yue GONG
	Peng GU
	Bing-bing XU
	Jin LI
	Xi-chen ZHAO

Cite this article:

YUN Tao,GONG Yue,GU Peng,XU Bing-bing,LI Jin,ZHAO Xi-chen. Present Situation and Prospect of International S&T Cooperation between China and Countries Participating in the “Belt and Road” Initiative to Combat COVID-19. China Biotechnology, 2021, 41(7): 110-121.

URL:

https://manu60.magtech.com.cn/biotech/10.13523/j.cb.2106014 OR https://manu60.magtech.com.cn/biotech/Y2021/V41/I7/110

Table 1 Joint research of countries participating in the “Belt and Road” initiative with China (N≥10)

Fig.1 Research area of top10 countries in “Belt and Road” initiative with the most number of co-published paper with China

Fig.2 Sunburst chart of research theme based on the co-published papers of countries in “Belt and Road” initiative with China

Fig.3 Interational cooperation network based on the joint research of countries in “Belt and Road” initiative with China The node size is proportional to the paper number of each country, the thickness of the connection is proportional to the number of cooperation

Fig. 4 Cooperation strength of countries in “Belt and Road” initiative with based on the joint research China The bubble size indicates the strength of cooperation; The vertical axis represents the number of co-published paper; The horizontal axis indicates the region of the participating countries

Fig. 5 International cooperation project application on COVID-19 by countries in “Belt and Road” initiative with China (a) The number of declared cooperation projects by 8 countries (b) The distribution of research directions of cooperation projects (c) The distribution of cooperation types of declared projects

Fig. 6 Cooperation proposals recommended by countries in“Belt and Road” Initiative (a) The field distribution of cooperation proposals (b) The ranking of countries by the number of cooperation proposals

Table 2 Statistics table of the weights of the third round of Delphi investigation

Table 3 Weights of S&T cooperation

Table 4 Variability coefficient and repeatability (R) of S&T cooperation

Fig.7 Average level of each S &T cooperation in different regions of the globally

排序	国家	所在地区	联合研究	合作项目	合作建议	媒体报道	科技合作水平
1	新加坡	东南亚	0.23	0.50	0.05	0.04	0.82
2	巴基斯坦	南亚	0.27	0.25	0.00	0.05	0.57
3	意大利	南欧	0.35	0.05	0.04	0.02	0.46
4	俄罗斯	中东欧	0.05	0.20	0.10	0.03	0.38
5	泰国	东南亚	0.21	0.10	0.05	0.01	0.36
6	沙特阿拉伯	西亚	0.19	0.10	0.00	0.02	0.31
7	韩国	东亚	0.09	0.15	0.04	0.02	0.30
8	伊朗	西亚	0.13	0.05	0.00	0.02	0.20
9	土耳其	西亚	0.12	0.05	0.00	0.02	0.19
10	南非	撒哈拉以南非洲	0.08	0.10	0.00	0.01	0.19
11	奥地利	中东欧	0.08	0.05	0.02	0.01	0.16
12	马来西亚	东南亚	0.11	0.00	0.01	0.03	0.15
13	葡萄牙	南欧	0.07	0.05	0.00	0.01	0.13
14	罗马尼亚	中东欧	0.06	0.05	0.01	0.01	0.13
15	印度尼西亚	东南亚	0.04	0.05	0.03	0.01	0.13
16	古巴	加勒比地区	0.01	0.10	0.00	0.01	0.12
17	波兰	中东欧	0.04	0.05	0.01	0.03	0.12
18	保加利亚	中东欧	0.01	0.05	0.04	0.02	0.11
19	孟加拉国	南亚	0.05	0.05	0.00	0.01	0.11
20	阿联酋	西亚	0.02	0.05	0.00	0.02	0.09
21	柬埔寨	东南亚	0.00	0.05	0.00	0.04	0.09
22	乌兹别克斯坦	中亚	0.00	0.05	0.01	0.03	0.09
23	埃及	北非	0.08	0.00	0.00	0.00	0.08
24	越南	东南亚	0.07	0.00	0.00	0.01	0.08
25	秘鲁	南美洲	0.03	0.05	0.00	0.00	0.08
26	突尼斯	北非	0.01	0.05	0.00	0.00	0.06
27	科摩罗	撒哈拉以南非洲	0.00	0.05	0.00	0.00	0.05
28	尼日利亚	撒哈拉以南非洲	0.05	0.00	0.00	0.00	0.05
29	希腊	南欧	0.03	0.00	0.00	0.02	0.05
30	菲律宾	东南亚	0.03	0.00	0.00	0.02	0.05
31	匈牙利	中东欧	0.02	0.00	0.01	0.01	0.05
32	新西兰	大洋洲	0.04	0.00	0.00	0.00	0.04
33	斯里兰卡	南亚	0.00	0.00	0.00	0.03	0.03
34	白俄罗斯	中东欧	0.00	0.00	0.00	0.03	0.03
35	科威特	西亚	0.01	0.00	0.00	0.02	0.03
36	斯洛文尼亚	中东欧	0.02	0.00	0.00	0.01	0.03
37	厄瓜多尔	南美洲	0.02	0.00	0.00	0.01	0.03
38	塞浦路斯	南欧	0.01	0.00	0.00	0.02	0.03
39	捷克	中东欧	0.02	0.00	0.00	0.01	0.03
40	伊拉克	西亚	0.02	0.00	0.00	0.01	0.03
排序	国家	所在地区	联合研究	合作项目	合作建议	媒体报道	科技合作水平
41	肯尼亚	撒哈拉以南非洲	0.02	0.00	0.00	0.01	0.03
42	蒙古	东亚	0.01	0.00	0.00	0.02	0.03
43	黎巴嫩	西亚	0.01	0.00	0.00	0.02	0.03
44	尼泊尔	南亚	0.02	0.00	0.00	0.01	0.03
45	乌克兰	中东欧	0.00	0.00	0.01	0.01	0.03
46	立陶宛	中东欧	0.01	0.00	0.01	0.01	0.03
47	斯洛伐克	中东欧	0.00	0.00	0.00	0.02	0.02
48	亚美尼亚	西亚	0.00	0.00	0.00	0.02	0.02
49	老挝	东南亚	0.00	0.00	0.00	0.02	0.02
50	阿塞拜疆	西亚	0.00	0.00	0.00	0.02	0.02
51	波黑	中东欧	0.00	0.00	0.00	0.02	0.02
52	纳米比亚	撒哈拉以南非洲	0.00	0.00	0.00	0.02	0.02
53	卡塔尔	西亚	0.01	0.00	0.00	0.01	0.02
54	苏丹	北非	0.01	0.00	0.00	0.01	0.02
55	也门	西亚	0.01	0.00	0.00	0.01	0.02
56	塞尔维亚	中东欧	0.00	0.00	0.00	0.02	0.02
57	东帝汶	东南亚	0.00	0.00	0.00	0.02	0.02
58	缅甸	南亚	0.00	0.00	0.00	0.02	0.02
59	文莱	东南亚	0.00	0.00	0.00	0.02	0.02
60	阿富汗	西亚	0.00	0.00	0.00	0.02	0.02
61	哈萨克斯坦	中亚	0.00	0.00	0.00	0.02	0.02
62	吉尔吉斯斯坦	中亚	0.00	0.00	0.00	0.02	0.02
63	黑山	中东欧	0.00	0.00	0.00	0.02	0.02
64	塞内加尔	撒哈拉以南非洲	0.01	0.00	0.00	0.01	0.02
65	阿曼	西亚	0.01	0.00	0.00	0.01	0.02
66	莫桑比克	撒哈拉以南非洲	0.01	0.00	0.00	0.01	0.02
67	克罗地亚	中东欧	0.01	0.00	0.00	0.01	0.02
68	卢森堡	中东欧	0.00	0.00	0.00	0.01	0.01
69	爱沙尼亚	中东欧	0.00	0.00	0.00	0.01	0.01
70	摩洛哥	北非	0.00	0.00	0.00	0.01	0.01
71	乌干达	撒哈拉以南非洲	0.01	0.00	0.00	0.00	0.01
72	加纳	撒哈拉以南非洲	0.01	0.00	0.00	0.00	0.01
73	马耳他	南欧	0.00	0.00	0.00	0.01	0.01
74	格鲁吉亚	西亚	0.00	0.00	0.00	0.01	0.01
75	北马其顿	中东欧	0.00	0.00	0.00	0.01	0.01
76	塞拉利昂	撒哈拉以南非洲	0.00	0.00	0.00	0.01	0.01
77	马尔代夫	南亚	0.00	0.00	0.00	0.01	0.01
78	巴林	西亚	0.00	0.00	0.00	0.01	0.01
79	塔吉克斯坦	中亚	0.00	0.00	0.00	0.01	0.01
80	阿尔巴尼亚	中东欧	0.00	0.00	0.00	0.01	0.01
81	拉脱维亚	中东欧	0.00	0.00	0.00	0.01	0.01
82	摩尔多瓦	中东欧	0.00	0.00	0.00	0.01	0.01
83	巴布亚新几内亚	大洋洲	0.00	0.00	0.00	0.01	0.01
84	纽埃	大洋洲	0.00	0.00	0.00	0.01	0.01
85	库克群岛	大洋洲	0.00	0.00	0.00	0.01	0.01
86	苏里南	南美洲	0.00	0.00	0.00	0.01	0.01
87	多米尼加	加勒比地区	0.00	0.00	0.00	0.01	0.01
88	特立尼达和多巴哥	加勒比地区	0.00	0.00	0.00	0.01	0.01
89	安提瓜和巴布达	加勒比地区	0.00	0.00	0.00	0.01	0.01
90	多米尼克	加勒比地区	0.00	0.00	0.00	0.01	0.01
91	巴巴多斯	加勒比地区	0.00	0.00	0.00	0.01	0.01
92	牙买加	加勒比地区	0.00	0.00	0.00	0.01	0.01
93	智利	南美洲	0.01	0.00	0.00	0.00	0.01

Table 5 S&T Cooperation between countries in “Belt and Road” initiative and China in combating COVID-19


[1]	国家信息中心. 中国一带一路专题. [2021-04-25]. https://www.yidaiyilu.gov.cn/ .

[1]	The State Information Center. BELT AND ROAD PORTAL. [2021-04-25]. https://www.yidaiyilu.gov.cn/ .

[2]	Gong Y, Ma T C, Xu Y Y, et al. Early research on COVID-19: a bibliometric analysis. The Innovation, 2020, 1(2):100027. doi: 10.1016/j.xinn.2020.100027

[3]	Ding Z Y, Chen H S, Liu J Y, et al. Pyrolysis dynamics of two medical plastic wastes: drivers, behaviors, evolved gases, reaction mechanisms, and pathways. Journal of Hazardous Materials, 2021, 402:123472. doi: 10.1016/j.jhazmat.2020.123472

[4]	Lin Y L, Hu Z J, Zhao Q J, et al. Understanding COVID-19 vaccine demand and hesitancy: a nationwide online survey in China. PLoS Neglected Tropical Diseases, 2020, 14(12):e0008961. doi: 10.1371/journal.pntd.0008961

[5]	Pagliusi S, Jarrett S, Hayman B, et al. Emerging manufacturers engagements in the COVID-19 vaccine research, development and supply. Vaccine, 2020, 38(34):5418-5423. doi: S0264-410X(20)30795-7 pmid: 32600908

[6]	Gruetzmacher K, Karesh W B, Amuasi J H, et al. The Berlin principles on one health - bridging global health and conservation. Science of the Total Environment, 2021, 764:142919. doi: 10.1016/j.scitotenv.2020.142919

[7]	Wiwanitkit V, Joob B. Density of COVID-19 and mass population movement during long holiday: simulation comparing between using holiday postponement and no holiday postponement. Journal of Research in Medical Sciences, 2020, 25:55. doi: 10.4103/jrms.JRMS_300_20 pmid: 32765625

[8]	Quiles J L, Rivas-García L, Varela-López A, et al. Do nutrients and other bioactive molecules from foods have anything to say in the treatment against COVID-19. Environmental Research, 2020, 191:110053. doi: S0013-9351(20)30950-6 pmid: 32835682

[9]	Hu X M, Zhu L X, Luo Y J, et al. Evaluation of the clinical performance of single-, dual-, and triple-target SARS-CoV-2 RT-qPCR methods. Clinica Chimica Acta, 2020, 511:143-148. doi: 10.1016/j.cca.2020.10.008

[10]	Moore S C, Penrice-Randal R, Alruwaili M, et al. Amplicon-based detection and sequencing of SARS-CoV-2 in nasopharyngeal swabs from patients with COVID-19 and identification of deletions in the viral genome that encode proteins involved in interferon antagonism. Viruses, 2020, 12(10):1164. doi: 10.3390/v12101164

[11]	Haq W, Raza S H, Mahmood T. The pandemic paradox: domestic violence and happiness of women. PeerJ, 2020, 8:e10472. doi: 10.7717/peerj.10472

[12]	Ntaios G, Michel P, Georgiopoulos G, et al. Characteristics and outcomes in patients with COVID-19 and acute ischemic stroke: the global COVID-19 stroke registry. Stroke, 2020, 51(9):e254-e258.

[13]	Marois G, Muttarak R, Scherbov S. Assessing the potential impact of COVID-19 on life expectancy. PLoS One, 2020, 15(9):e0238678.

[14]	Silvin A, Chapuis N, Dunsmore G, et al. Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell, 2020, 182(6):1401-1418, e18. doi: 10.1016/j.cell.2020.08.002

[15]	Zhong M, Lin B P, Pathak J L, et al. ACE2 and furin expressions in oral epithelial cells possibly facilitate COVID-19 infection via respiratory and fecal-oral routes. Frontiers in Medicine, 2020, 7:580796. doi: 10.3389/fmed.2020.580796

[16]	Mavian C, Pond S K, Marini S, et al. Sampling bias and incorrect rooting make phylogenetic network tracing of SARS-COV-2 infections unreliable. PNAS, 2020, 117(23):12522-12523. doi: 10.1073/pnas.2007295117 pmid: 32381734

[17]	Deng X, Shao H J, Shi L, et al. A classification-detection approach of COVID-19 based on chest X-ray and CT by using keras pre-trained deep learning models. Computer Modeling in Engineering & Sciences, 2020, 125(2):579-596.

[18]	Chang K C, Hou W L, Pakpour A H, et al. Psychometric testing of three COVID-19-related scales among people with mental illness. International Journal of Mental Health and Addiction, 2020: 1-13.

[19]	丁洁兰, 杨立英, 孙海荣, 等. 基于文献计量的“一带一路”区域及沿线国家科研合作态势研究. 中国科学院院刊, 2017, 32(6):626-636.

[19]	Ding J L, Yang L Y, Sun H R, et al. Bibliometric study on research collaboration among the Belt and Road areas and countries. Bulletin of Chinese Academy of Sciences, 2017, 32(6):626-636.

[1]	CHEN Chen,HU Jin-chao,CAO Shan-shan,MEN Dong. The Development of Antigen Testing for SARS-CoV-2[J]. China Biotechnology, 2021, 41(6): 119-128.

[2]	XU Ye-chun,LIU Hong,LI Jian-feng,SHEN Jing-shan,JIANG Hua-liang. Recent Progress in Drug Development against COVID-19[J]. China Biotechnology, 2021, 41(6): 111-118.

[3]	SHI Rui,YAN Jing-hua. Research Progress of Neutralizing Antibody Drugs against SARS-CoV-2[J]. China Biotechnology, 2021, 41(6): 129-135.

[4]	ZHANG Sai,WANG Gang,LIU Zhong-ming,LI Hui-jun,WANG Da-ming,QIAN Chun-gen. Development and Performance Evaluation of a Rapid Antigen Test for SARS-CoV-2[J]. China Biotechnology, 2021, 41(5): 27-34.

[5]	FAN Yue-lei,WANG Yue,WANG Heng-zhe,LI Dan-dan,MAO Kai-yun. *Research Progress of in Vitro* Diagnostic Technologies for SARS-CoV-2**[J]. China Biotechnology, 2021, 41(2/3): 150-161.

[6]	FU Gui-e,LI Jin,GENG Pei-ran,SHEN Meng-qiu,ZHANG Jin-qian-nan,ZHAO Xi-chen. A Study on COVID-19 Prevention Force of Typical Cities in the Guangdong-Hong Kong-Macao Greater Bay Area Based on the Medical Perspective[J]. China Biotechnology, 2021, 41(12): 125-140.

[7]	WU Rui-jun,LI Zhi-fei,ZHANG Xin,PU Run,AO Yi,SUN Yan-rong. Development and Prospect of Antibody Drugs for SARS-CoV-2[J]. China Biotechnology, 2020, 40(5): 1-6.

[8]	XIE Hua-ling,LV Lu-cheng,YANG Yan-ping. Patent Analysis of Global Coronavirus Vaccine[J]. China Biotechnology, 2020, 40(1-2): 57-64.

[9]	PAN Tong-tong,CHEN Yong-ping. Research Progress of Key Techniques for Severe/Critical Type of Novel Coronavirus Pneumonia[J]. China Biotechnology, 2020, 40(1-2): 78-83.

[10]	ZHU Xiao-li,HUANG Cui,MA Li-li,ZHANG Chao,GONG Yue,ZHAO Wan-yu,ZHAO Xiu-fang,GUO Wen-jiao,PENG Hao,ZHANG Ji,LIANG Hui-gang. Research Advances of Novel Coronavirus Disease (COVID-19)[J]. China Biotechnology, 2020, 40(1-2): 38-50.

[11]	LIAO Xiao-yan,CHEN Li-li. The Progress in the Development of COVID-19 Vaccine[J]. China Biotechnology, 2020, 40(12): 8-17.

[12]	LIN Fu-yu,LIU Jin-yi,CHENG Yong-qing. Progress of Interferon α1b Research and Clinical Use Against SARS-CoV-2[J]. China Biotechnology, 2020, 40(12): 1-7.

[13]	CHEN Li-jun,QU Jing-jing,XIANG Charlie. Therapeutic Potentials, Clinical Studies, and Application Prospects of Mesenchymal Stem Cells in 2019 Novel Coronavirus (COVID-19)[J]. China Biotechnology, 2020, 40(11): 43-55.

Viewed

Full text

Abstract

Cited

Shared

Discussed